Vical’s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses
With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine

Vical’s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses
With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine

SAN DIEGO, Oct. 26, 2009 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL)
announced today the publication of two articles regarding the company’s
Vaxfectin(R) adjuvant in a special issue of Vaccine.(1,2) One article
highlighted preclinical data showing Vaxfectin(R)’s improvement of performance
with Sanofi-Pasteur Fluzone(R) seasonal influenza vaccine; the other analyzed
how Vaxfectin(R) works.

“Vaxfectin(R) is a powerful new adjuvant for a broad range of infectious disease
and cancer vaccine applications,” said Alain P. Rolland, Pharm.D., Ph.D.,
Vical’s Executive Vice President of Product Development. “These latest data
expand our understanding of Vaxfectin(R)’s mechanism of action and the breadth
of its abilities as an adjuvant to increase antibody and/or T-cell responses. We
are currently evaluating Vaxfectin(R) with DNA-, protein- and peptide-based
vaccines both independently and with collaborators.”

Read more here

Related posts:

1. Vical hits goals in pandemic vaccine development
2. Sanofi buys into Indian biotech
3. Sanofi-Aventis and the Salk Institute establish regenerative medicine research alliance
4. SD News: Sanofi-aventis To Acquire TargeGen, Inc.
5. Sanofi to buy U.S. group Chattem for $1.9 billion